HEMOPHILIA AIDS CLINICAL TRIALS INITIATIVE

此次收购的目的是维护由 国家血友病基金会(NHF)招募和跟踪艾滋病毒感染者 血友病患者及其配偶参加艾滋病临床试验。这项工作将是 根据本合同完成的工作将是已完成工作的延续 由国家血友病基金会通过根据 RFP-NIH-NIAID-AIDS P-88-16。 NHF将参加艾滋病临床试验小组，以及 为临床开发I、II和III期试验的组织 研究。在一个典型的合同年期间，NHF将拥有 获得各种I期、II期和III期临床研究方案 旨在测试各种治疗初发艾滋病病毒的疗法 感染与机会性感染的防治 和癌症。在这些研究中，国家血友病基金会 威尔选择了适合其人口的研究(一般为3-6项)。这个 研究的目的是治疗各种不同的临床表现 血友病患者及其配偶中的艾滋病毒感染。

The purpose of this acquisition is to maintain the system developed by the National Hemophilia Foundation (NHF) to recruit and follow HIV infected hemophiliacs and their spouses on AIDS clinical trials. The work to be performed under this contract will be a continuation of the work performed by the National Hemophilia Foundation through a contract awarded under RFP-NIH-NIAID-AIDS P-88-16. The NHF will be participating in the AIDS Clinical Trials Group, an organization which develops Phase I, II, and III trials for clinical research. Over the course of a typical contract year the NHF will have access to a variety of Phase I, II, and III clinical research protocols designed to test various therapies for the treatment of primary HIV infection and the prophylaxis and treatment of opportunistic infections and cancers. Out of these studies, the National Hemophilia Foundation will chose studies (generally 3 - 6) suitable for its population. The purpose of the research studies is to treat the various manifestations of HIV infection in hemophiliacs and their spouses.